Abstract:MRI contrast agents such as paramagnetic Gd(iii)-chelates, can improve the ability of MRI in differentiating diseased and healthy tissues, and have been widely used in clinical diagnosis. However, the enhancement effect of small molecular MRI contrast agents is unsatisfied due to their relative high rotation rates. Furthermore, the small molecular contrast agents also suffer from the short blood half-life and nonspecific extracellular diffusion in tissues, which also restricts their applications. To address these issues, we developed a macromolecular MRI contrast agent based on a zwitterionic metal-chelating polymer. Poly(acrylic acid) (PAA) was chosen as the main chain, and diethylenetriamine pentaacetic acid (DTPA) as the metal-chelating group was coupled through the carboxyl groups of PAA using diethylenetriamine (DET) as a linker. The macromolecular MRI contrast agent constructed by chelating with Gd3+(Gd-PAA) exhibited a much higher longitudinal relaxation rate (r(1)) than the clinical contrast agent Gd-DTPA. Importantly, due to the stealth ability of the zwitterionic structure, Gd-PAA can reside in the blood long enough without any microvascular leakage in the extracellular space of normal tissues, which allows it to be used for precise blood MR imaging, such as hepatorenal angiography, but also for tumor imaging because of the enhanced permeability and retention (EPR) effecta. Besides, the result of long-term toxicity tests highlights the safety feature of the current contrast agent. Hence, the current contrast agent overcomes the defect of traditional small molecular Gd(iii)-basedT(1)-weighted contrast agents and shows great prospects for future clinical applications.

Chiral Gd-DOTA as a Versatile Platform for Hepatobiliary and Tumor Targeting MRI Contrast Agents

Rational Design of Gd-DOTA-Type Contrast Agents for Hepatobiliary Magnetic Resonance Imaging

A Targeted Nanoglobular Contrast Agent from Host-Guest Self-Assembly for MR Cancer Molecular Imaging.

Design and synthesis of chiral DOTA-based MRI contrast agents with remarkable relaxivities

Gadolinium-based contrast agents for tumor targeting imaging

Liver-targeting MRI Contrast Agent Based on Galactose Functionalized O-Carboxymethyl Chitosan

Rational Design of Mono-Substituted Gd-DOTA as Highly Stable and Efficient MRI Contrast Agents for Hepatobiliary and Inflammation Imaging

A neutral polydisulfide containing Gd(III) DOTA monoamide as a redox‐sensitive biodegradable macromolecular MRI contrast agent

Albumin-based Nanoparticles Loaded with Hydrophobic Gadolinium Chelates As T1-T2 Dual-Mode Contrast Agents for Accurate Liver Tumor Imaging.

Single-Atom Gadolinium Nano-Contrast Agents with High Stability for Tumor T 1 Magnetic Resonance Imaging

Gadolinium‐based Contrast Agents for Magnetic Resonance Cancer Imaging

Gadolinium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugate of arabinogalactan as a potential liver-targeting magnetic resonance imaging contrast agent.

An MRI contrast agent based on a zwitterionic metal-chelating polymer for hepatorenal angiography and tumor imaging.

Gadolinium(III) Chelated Conjugated Polymer As a Potential MRI Contrast Agent

Synthesis and preliminary evaluation of gadolinium complexes containing sulfonamide groups as potential MRI contrast agents

Single-Atom Gadolinium Nano-Contrast Agents with High Stability for Tumor <i>T</i><sub>1</sub> Magnetic Resonance Imaging

Biodegradable Nanoglobular Magnetic Resonance Imaging Contrast Agent Constructed with Host-Guest Self-Assembly for Tumor-Targeted Imaging.

Chiral Pyclen-Based Heptadentate Chelates as Highly Stable MRI Contrast Agents

Preparation and performance of biocompatible gadolinium polymer as liver-targeting magnetic resonance imaging contrast agent

A Hyaluronic Acid-Chitosan-Gadolinium Nanosphere for Specific Tumor-Targeted MRI Contrast Agent

Hyaluronic Acid-Chitosan Nanoparticles to Deliver Gd-DTPA for MR Cancer Imaging